Special Issue

Approaches in Hepatitis Vaccine Design and Vaccination Strategy

Message from the Guest Editor

Hepatitis B virus (HBV) causes both acute and chronic liver diseases. Chronic HBV infection can lead to severe complications. Recent studies suggest that HBV vaccines may offer therapeutic benefits; therefore, there is a need for new strategies to develop more effective treatments and vaccines to control HBV infection. Therapeutic vaccines, particularly hepatitis B, are in development. They are designed to treat chronic infections by stimulating the body's immune system to clear the virus. While no therapeutic vaccine has yet achieved a functional cure, these vaccines are designed differently from preventative ones, often combining multiple viral antigens and sometimes using novel platforms like mRNA to induce a more potent and specific immune response capable of controlling. There is a need for further development of therapeutic vaccines concerning their composition, antigens, dosages, and methods of administration. This Special Issue will focus on addressing vaccine-related issues to achieve the overarching goal of the "Elimination of Hepatitis" in the near future. We look forward to receiving your contributions.

Guest Editor

Dr. Sheikh Mohammad Fazle Akbar
Department of Gastroenterology and Metabology, Graduate School of Medicine, Ehime University, Toon 791-0295, Japan

Deadline for manuscript submissions

30 September 2026

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/259676

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

MDPI